| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Hematology and Oncology,
Departments of Pathology,
Urology, and
Biostatistics, Wayne State University, and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201;
¶ Department of Medicine, McGill University and Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada;
+ Joint Institute for Applied Nutrition, Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742; and
** Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii 96813
Epidemiological studies have shown an inverse association between dietary intake of lycopene and prostate cancer risk. We conducted a clinical trial to investigate the biological and clinical effects of lycopene supplementation in patients with localized prostate cancer. Twenty-six men with newly diagnosed prostate cancer were randomly assigned to receive a tomato oleoresin extract containing 30 mg of lycopene (n = 15) or no supplementation (n = 11) for 3 weeks before radical prostatectomy. Biomarkers of cell proliferation and apoptosis were assessed by Western blot analysis in benign and cancerous prostate tissues. Oxidative stress was assessed by measuring the peripheral blood lymphocyte DNA oxidation product 5-hydroxymethyl-deoxyuridine (5-OH-mdU). Usual dietary intake of nutrients was assessed by a food frequency questionnaire at baseline. Prostatectomy specimens were evaluated for pathologic stage, Gleason score, volume of cancer, and extent of high-grade prostatic intraepithelial neoplasia. Plasma levels of lycopene, insulin-like growth factor-1, insulin-like growth factor binding protein-3, and prostate-specific antigen were measured at baseline and after 3 weeks of supplementation or observation. After intervention, subjects in the intervention group had smaller tumors (80% vs 45%, less than 4 ml), less involvement of surgical margins and/or extra-prostatic tissues with cancer (73% vs 18%, organ-confined disease), and less diffuse involvement of the prostate by high-grade prostatic intraepithelial neoplasia (33% vs 0%, focal involvement) compared with subjects in the control group. Mean plasma prostate-specific antigen levels were lower in the intervention group compared with the control group. This pilot study suggests that lycopene may have beneficial effects in prostate cancer. Larger clinical trials are warranted to investigate the potential preventive and/or therapeutic role of lycopene in prostate cancer.
Key Words: lycopene • prostate cancer • chemoprevention • treatment • connexin • tomato carotenoids
This article has been cited by other articles:
|
|
 |
|
  N. Sahin, C. Orhan, M. Tuzcu, K. Sahin, and O. Kucuk The Effects of Tomato Powder Supplementation on Performance and Lipid Peroxidation in Quail Poult. Sci., February 1, 2008; 87(2): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Syed, N. Khan, F. Afaq, and H. Mukhtar Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2193 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liu, R. M. Russell, and X.-D. Wang Lycopene Supplementation Prevents Smoke-Induced Changes in p53, p53 Phosphorylation, Cell Proliferation, and Apoptosis in the Gastric Mucosa of Ferrets J. Nutr., January 1, 2006; 136(1): 106 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Chan, P. H. Gann, and E. L. Giovannucci Role of Diet in Prostate Cancer Development and Progression J. Clin. Oncol., November 10, 2005; 23(32): 8152 - 8160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sicilia, A. Bub, G. Rechkemmer, K. Kraemer, P. P. Hoppe, and S. E. Kulling Novel Lycopene Metabolites Are Detectable in Plasma of Preruminant Calves after Lycopene Supplementation J. Nutr., November 1, 2005; 135(11): 2616 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Hantz, L. F. Young, and K. R. Martin Physiologically Attainable Concentrations of Lycopene Induce Mitochondrial Apoptosis in LNCaP Human Prostate Cancer Cells Experimental Biology and Medicine, March 1, 2005; 230(3): 171 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tang, T. Jin, X. Zeng, and J.-S. Wang Lycopene Inhibits the Growth of Human Androgen-Independent Prostate Cancer Cells In Vitro and in BALB/c Nude Mice J. Nutr., February 1, 2005; 135(2): 287 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]
|
|
|
|
|
|
S. Zaripheh, T. W.-M. Boileau, M. A. Lila, and J. W. Erdman Jr [14C]-Lycopene and [14C]-Labeled Polar Products Are Differentially Distributed in Tissues of F344 Rats Prefed Lycopene J. Nutr., December 1, 2003; 133(12): 4189 - 4195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. C. Obermuller-Jevic, E. Olano-Martin, A. M. Corbacho, J. P. Eiserich, A. van der Vliet, G. Valacchi, C. E. Cross, and L. Packer Lycopene Inhibits the Growth of Normal Human Prostate Epithelial Cells in Vitro J. Nutr., November 1, 2003; 133(11): 3356 - 3360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Forbes, K. Gillette, and I. Sehgal Lycopene Increases Urokinase Receptor and Fails to Inhibit Growth or Connexin Expression in a Metastatically Passaged Prostate Cancer Cell Line: A Brief Communication Experimental Biology and Medicine, September 1, 2003; 228(8): 967 - 971. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
